MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E. V. (Allemagne)
Inventeur(s)
Cabezas-Wallscheid, Nina
Romero Mulero, Maria Del Carmen
Rettkowski, Jasmin
Abrégé
The present invention relates to 4-oxoretinoate for use in treatment or prevention of cardiac dysfunction, heart failure, or adverse cardiac remodelling after myocardial infarction or impaired cardiac blood flow. The present invention also relates to 4-oxoretinoate for use in treatment of coronary artery disease, or of ischemia-reperfusion injury.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
2.
COMPOSITION FOR ABSORBING ULTRAVIOLET ELECTROMAGNETIC RADIATION, SUBSTRATE COMPRISING A COATING AND METHOD FOR PROTECTING A SURFACE OF A SUBSTRATE
nn-R with Ar, X, n and R as defined in the specification, particularly the UV absorbing agent is cinnamic acid, cinnamyl alcohol or gallic acid, or a derivative thereof. The invention further relates to a substrate comprising a coating and a method for protecting a surface of a substrate from UV electromagnetic radiation.
The present invention is directed to a method for manufacturing a bioresorbable polymeric medical implant and a polymeric composition for use in such a method. The inventive polymer blend comprises a PCL/PLA mixture in solution, and further comprises a compatibilizer. The inventive method comprises producing the inventive polymeric composition, and using said polymeric composition to form the selected implant, followed by heat treatment.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 27/58 - Matériaux au moins partiellement résorbables par le corps
A61L 31/06 - Matériaux macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
C08L 67/04 - Polyesters dérivés des acides hydroxycarboxyliques, p. ex. lactones
A photodetector (PD), comprises: a photonic layer (1) which includes a widening section (12) followed by a wide section (13), wherein the widening section (12) is configured to receive an optical signal (oS) and to distribute optical power of the optical signal (oS) to the wide section (13); a spacer layer (2) which is in contact with the wide section (13); a 2D material layer (3) which is in contact with the spacer layer (2); a plasmonic layer (4) which is in contact with the 2D material layer (3) and includes a plurality of plasmonic resonators (411, 421) which are connected via contact lines (412, 422) to connector lines (413, 423), wherein the connector lines (413, 423) enable to measure charge carriers which are generated upon receipt of the optical signal (oS).
H10F 30/22 - Dispositifs individuels à semi-conducteurs sensibles au rayonnement dans lesquels le rayonnement commande le flux de courant à travers les dispositifs, p. ex. photodétecteurs les dispositifs ayant des barrières de potentiel, p. ex. phototransistors les dispositifs étant sensibles au rayonnement infrarouge, visible ou ultraviolet les dispositifs ayant une seule barrière de potentiel, p. ex. photodiodes
H10F 77/14 - Forme des corps semi-conducteursFormes, dimensions relatives ou dispositions des régions semi-conductrices au sein des corps semi-conducteurs
The present invention relates to the provision of trifunctional crosslinker compounds comprising (i) a moiety reactive with an amino acid side chain for selective labelling of proteins, (ii) a cleavable linker moiety and (iii) an affinity moiety for the detection, isolation and purification of captured proteins. The invention further relates to uses of the cleavable crosslinking reagents in methods for detecting, labelling, identifying and characterizing proteins and protein interactions in or on the surface of intact cells, cell lysates and/or protein mixtures.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07K 5/04 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés ne comportant que des liaisons peptidiques normales
A DNA sequence and a synthetic gene circuit (SGC) comprising the same for detecting a DNA or RNA nucleotide trigger sequence, associated detection systems, methods for detecting the DNA or RNA nucleotide trigger sequence as well as further proteins of interest and associated uses.
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
7.
ULK1 INHIBITOR FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE
The invention relates to a ULK1 inhibitor for use in the treatment of a human or mammalian patient being diagnosed for, suffering from, or being at risk of developing a neurodegenerative disease, or in the prevention of such condition.
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The invention refers to an apparatus for powder-based additive manufacturing of three-dimensional structures on a platform (4). The apparatus comprises a powder delivery mechanism (100) with a first powder chamber (11) for a first powder with a first powder outlet, and a second powder chamber (12) for a second powder with a second powder outlet. In addition, the powder delivery mechanism (100) comprises a gating mechanism (3) with a first slot (31) and a second slot (32), wherein the powder delivery mechanism (100) and/or the platform (4) are rotatable around a platform center axis (10) of the platform (4), wherein the gating mechanism (3) is arranged such that the first slot (31) defines an outlet surface of the first powder outlet and the second slot (32) defines an outlet surface of the second powder outlet, wherein the gating mechanism (3) is displaceable relatively to the first powder outlet and/or the second powder outlet.
B22F 10/28 - Fusion sur lit de poudre, p. ex. fusion sélective par laser [FSL] ou fusion par faisceau d’électrons [EBM]
B22F 12/00 - Appareils ou dispositifs spécialement adaptés à la fabrication additiveMoyens auxiliaires pour la fabrication additiveCombinaisons d’appareils ou de dispositifs pour la fabrication additive avec d’autres appareils ou dispositifs de traitement ou de fabrication
B29C 64/153 - Procédés de fabrication additive n’utilisant que des matériaux solides utilisant des couches de poudre avec jonction sélective, p. ex. par frittage ou fusion laser sélectif
The present invention relates to a combination therapy against pathogenic bacteria in the gut, wherein a bacteriophage against the capsule of the pathogenic bacterium is combined with a vaccination against a bacterial antigen which is normally masked by the capsule.
The present invention relates to a method for screening engineered antibody Fc regions having modified Fc receptor binding properties, the method comprising the steps of: (a) providing a plurality of cells displaying engineered antibody Fc regions on their cell surface, preferably wherein each cell comprised in the plurality of cells displays an engineered antibody Fc region comprising at least one mutation; (b) contacting the cells in step (a) with an Fc receptor; (c) separating cells that have been contacted with the Fc receptor in step (b) into two or more cell populations according to their ability to bind to the Fc receptor, preferably wherein the ability of an engineered antibody Fc region to bind to the Fc receptor is determined by comparison with a reference antibody Fc region; and (d) sequencing cells from at least one of the populations obtained in step (c), preferably to identify mutations in the engineered antibody Fc region that (i) confer improved binding to the Fc receptor, (ii) do not affect binding to the Fc receptor, and/or (iii) confer reduced binding to the Fc receptor. Further provided herein are methods for predicting the Fc receptor binding properties of an engineered antibody Fc region, as well as methods for generating an engineered antibody Fc region having desired Fc receptor binding properties
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p. ex. bibliothèques de gènes
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
12.
COMPOUNDS COMPRISING NON-CANONICAL AMINO ACIDS AND USES THEREOF
Provided herein are compounds comprising an isopeptide-linked lysine or an analog thereof. Further provided herein are methods for engineering peptide-binding proteins having increased affinity and/or selectivity for the compound according to the invention, as well as peptide-binding proteins with increased selectivity for the compound according to the invention. Moreover, methods for incorporating non-canonical amino acids into proteins are provided herein.
C07K 5/02 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
13.
DEVICES AND METHODS FOR DETERMINING SPATIOTEMPORAL REFRACTIVE INDEX CHANGES
A measurement assembly for determining refractive index changes in a sample comprises a light source (2), a tunable wavelength selector (3), an image sensor (4), a processing unit (6), and a Fabry-Perot unit (5) comprising a first plane surface (51) and a second plane surface (52), the Fabry-Perot unit (5) having a sample reception space (53) arranged between the first plane surface (51) and the second plane surface (52) to receive a sample. The Fabry-Perot unit (5) is arranged to act as a wavelength-dependent light intensity filter. The image sensor (4) is configured to record a two-dimensional image of the sample reception space for different spectral subranges and the processing unit (6) is configured to reconstruct the intensity filter function of the Fabry-Perot unit (5) based on the recorded two-dimensional images, and to determine a refractive index map based on the reconstructed intensity filter function.
G01N 21/45 - RéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant des méthodes interférométriquesRéfringencePropriétés liées à la phase, p. ex. longueur du chemin optique en utilisant les méthodes de Schlieren
An apparatus for liquid handling, in particular of small liquid volumes, an associated method and use for liquid handling, in particular for receiving and/or dispensing a liquid, the apparatus comprising: a capillary; a plate; means for moving the capillary and/or the plate relative to each other; and a sensor (9).
A pupillometry system (100) for computer-implemented assessment of brain aging and presymptomatic Alzheimer's risk in cognitively unimpaired individuals through computer-human interaction with a user (5), wherein the pupillary moment-by-moment dynamics of the user on a sensory stimulation decision task with continuous or—at least two—discrete selection options and a subsequent reward/feedback choice is analyzed.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A61B 3/11 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la distance interpupillaire ou le diamètre de la pupille
A61B 5/16 - Dispositifs pour la psychotechnieTest des temps de réaction
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A connector assembly (100) for connecting external power sources to an implanted medical device has a distal driveline portion (102) and a proximal driveline portion (101), each comprising a plurality of isolated electricity wires (103) and at least one load carrying wire (104). An intermediate driveline assembly (300) is provided and adapted to arrange the electricity wires (103) and the load carrying wire(s) (104) in a flat plane (13) for a predetermined distance (11) in the longitudinal direction (10) of these wires (103, 104), wherein the electricity wires (103) and the load carrying wire(s) (104) are positioned in a spacing from each other over at least a part of this predetermined distance (11') in that plane (13).
A61M 60/178 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient implantables dans ou sur le cœur, ou autour du cœur prélevant le sang d’un ventricule et renvoyant le sang vers le système artériel par une canule externe au ventricule, p. ex. dispositifs d’assistance pour ventricule gauche ou droit
A61M 60/216 - Pompes pour le sang à déplacement non positif comportant un élément rotatif agissant sur le sang, p. ex. un impulseur
A61M 60/878 - Connexions électriques dans le corps du patient
The present invention relates to a device (1) for reducing a particle density of a sample of a suspension of particles in a liquid, the device comprising a measurement flow path (13) for characterizing the sample of the suspension, wherein the device (1) is configured to withdraw a sample of the suspension residing in a main vessel (100), and to dilute the sample, particularly when a measure indicative of the particle density in the sample is above a pre-defined threshold.
G01N 1/38 - Dilution, dispersion ou mélange des échantillons
G01N 15/0227 - Recherche de la dimension ou de la distribution des dimensions des particules par des moyens optiques utilisant l’imagerieRecherche de la dimension ou de la distribution des dimensions des particules par des moyens optiques utilisant l’holographie
G01N 15/075 - Recherche de la concentration des suspensions de particules par des moyens optiques
18.
A LIPID EMULSION FOR BRAIN REGENERATION AND OPTIMIZING BRAIN DEVELOPMENT VIA PARENTERAL OR ENTERAL ADMINISTRATION
The present invention relates to a specific lipid emulsion comprising ≥ 5 % stearidonic acid and ≥ 15 % α-linolenic acid for use in neuroprotection, neuroregeneration and neurodevelopment.
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/201 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p. ex. acides oléique ou linoléique
A61K 31/202 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p. ex. acide linolénique
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
19.
SYSTEMS AND REACTORS FOR THE PRODUCTION OF AMMONIA
The present invention relates to systems and reactors for continuous production of ammonia. The systems are particularly suited to produce ammonia in decentralized, rural locations using temporal surplus electricity from renewable sources, thereby allowing the production of fertilizers in the location of need.
B01J 8/02 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solidesAppareillage pour de tels procédés avec des particules immobiles, p. ex. dans des lits fixes
The invention pertains to a method for controlling a reaction of a CRISPR Cas effector protein with a target, an associated CRISPR Cas effector protein and associated uses for detection, optionally detection of a nucleic acid in a biological sample or in a sample derived from a biological material.
The present invention relates to a method for dechlorinating chlorinated organic compounds in an electrochemical device comprising an undivided electrolytic cell with two electrodes acting as anode and cathode, by a) providing a composition comprising the chlorinated organic compounds, a solvent and a sacrificial electron donor, wherein the solvent can also function as the sacrificial electron donor, or alternatively, the solvent and the sacrificial electron donor are two separate components, and b) conducting an electrochemical reaction to dechlorinate the chlorinated organic compounds, characterized by alternating the polarity of the two electrodes, with both electrodes being graphite electrodes.
C02F 1/461 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par électrolyse
C02F 1/467 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par électrolyse par désinfection électrochimique
C02F 1/68 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par addition de substances spécifiées, pour améliorer l'eau potable, p. ex. par addition d'oligo-éléments
C02F 101/36 - Composés organiques contenant des atomes d'halogène
The invention relates to a method for making a micro-structured hydrogel, comprising the steps of: providing a hydrogel composition comprising a polymer crosslinked by linker moieties comprising a photolabile coumarin moiety, and subjecting the hydrogel composition to structured irradiation with light having a wavelength of ≥700 nm. The invention also relates to a micro-structured hydrogel composition, comprising a hydrogel crosslinked by moieties comprising a photolabile moiety susceptible to cleavage by two-photon irradiation of a wavelength of ≥700 nm, and channels or cavities having a diameter of ≤10 µm. In some embodiments, the hydrogel comprises a plurality of ellipsoid indentations (lacunae) on its surface, and a plurality of channels (canaliculi) departing from each lacuna.
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
C08J 3/28 - Traitement par ondes énergétiques ou par rayonnement de particules
C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C07D 311/08 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 2 non hydrogénés dans l'hétérocycle
C08G 65/48 - Polymères modifiés par post-traitement chimique
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
23.
GYROTRON SYSTEM COMPRISING INTEGRATED SUPERCONDUCTING MAGNET AND CAVITY
A gyrotron system (1) comprises a housing (2), an electron gun (3) configured to produce an electron beam, at least one magnet (4) configured to produce a magnetic field, and a cavity (5) configured to receive the electron beam, and wherein microwaves and/or Terahertz waves (16) are generatable in the cavity (5) by a resonance coupling between the electron beam and the magnetic field produced by the magnet (4). The magnet (4) is a superconducting magnet that is configured to exhibit superconductivity upon cooling below its critical temperature and that is arranged around the cavity (5), and the cavity (5) and the superconducting magnet (4) are arranged within the housing (2).
H01J 25/02 - Tubes à faisceau électronique modulé en vitesse ou en densité dans une zone modulatrice et cédant ensuite de l'énergie dans une zone inductrice, les zones étant associées à un ou plusieurs résonateurs
24.
AMMONIA CONCENTRATION DETECTION METHOD FOR AN INTERNAL COMBUSTION ENGINE
Method for calculating NH3 and NOx concentrations downstream from an SCR system of an internal combustion engine (E) of a vehicle by means of a statistical module, the method comprising the following steps: using temperature measurements acquired upstream (T1) and downstream (T2) of the Selective Reduction Catalyst (SCR) as first input variables and NOx mass flow measurements acquired upstream (N1) and downstream (N2) of the SCR as second input variables; calculating an NH3 concentration downstream from the SCR catalytic converter as a function of the first and second inputs.
A method of producing a deposition structure (1) on a substrate (2) comprises the steps of i) providing at least one depositor (3) for depositing at least one material (6), ii) providing at least one mask (4) comprising a plurality of apertures (5, 5a,...), iii) providing at least one substrate (2), and iv) depositing at least one material (6) from the depositor (3). Part of the material (6) passes through the apertures (5, 5a,...) of the mask (4) and is deposited on a surface (7) of the substrate (2), whereby at least one deposition structure (1) is formed on the surface (7) of the substrate (2). At least one tilting angle (φ) between i) the substrate (2) and/or the mask (4) and ii) the depositor (3) is at least temporarily changed before and/or during the deposition of the material (6). Additionally or alternatively, at least one rotating angle (θ) between i) the substrate (2) and/or the mask (4) and ii) the depositor (3) is at least temporarily changed before and/or during the deposition of the material (6).
C23C 14/04 - Revêtement de parties déterminées de la surface, p. ex. au moyen de masques
C23C 14/22 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le procédé de revêtement
C23C 14/52 - Dispositifs pour observer le processus de revêtement
C23C 14/54 - Commande ou régulation du processus de revêtement
H01L 21/308 - Traitement chimique ou électrique, p. ex. gravure électrolytique en utilisant des masques
H05B 33/10 - Appareils ou procédés spécialement adaptés à la fabrication des sources lumineuses électroluminescentes
H10K 71/16 - Dépôt d'une matière active organique en utilisant un dépôt physique en phase vapeur [PVD], p. ex. un dépôt sous vide ou une pulvérisation cathodique
G03F 9/00 - Mise en registre ou positionnement d'originaux, de masques, de trames, de feuilles photographiques, de surfaces texturées, p. ex. automatique
B82Y 40/00 - Fabrication ou traitement des nanostructures
The present invention is directed to a method for preparing 3-dimensional vascular models comprising the 3-dimensional imaging, printing and embedding of 3-dimensional vasculature and subsequent selective dissolution of the printed and embedded 3-dimensional vasculature in the 3-dimensional material. Furthermore, the present invention relates to the 3-dimensional vascular model prepared by the inventive method as well as to methods for the in vitro practice of a surgical method in an animal or human and a method for a surgical intervention in the vasculature of an animal or human in need thereof.
A method of manufacturing a jointless superconducting multi-coil (1, 1') comprises the steps of providing a superconducting element (2) and winding a first part (2b1) around at least part of a first mandrel (3) so as to form a first pre-coil (4) of a first coil (5), winding at least part around at least part of the first mandrel (3) so as to form the first coil (5), and i) winding a second part (2b2) around at least part of a second mandrel (6) so as to form a second pre-coil (7) of a second coil (8) and winding at least part around at least part of the second mandrel (6) so as to form the second coil (8), or ii) winding a second part (2b2) around at least part of the first mandrel (3) so as to form a second pre-coil (7') of a second coil (8') and winding at least part around at least part of the first mandrel (3) so as to form the second coil (8'). The multi-coil (1, 1') comprises the first coil (5) and the second coil (8, 8') being arranged above one another with respect to a longitudinal direction (Lc, Lc') of the multi-coil (1, 1').
H01F 41/04 - Appareils ou procédés spécialement adaptés à la fabrication ou à l'assemblage des aimants, des inductances ou des transformateursAppareils ou procédés spécialement adaptés à la fabrication des matériaux caractérisés par leurs propriétés magnétiques pour la fabrication de noyaux, bobines ou aimants pour la fabrication de bobines
H01F 6/06 - Bobines, p. ex. dispositions pour l'enroulement, l'isolation, les enveloppes ou les bornes des bobines
A material for storing thermal energy comprises or consists of a crosslinked polymer, wherein the crosslinked polymer comprises backbone chains, crosslinking chains, and side chains. The crosslinking chains link the backbone chains to one another. The side chains are attached to one site of the backbone chains. The side chains comprise a phase-change moiety, and wherein the phase-change moiety is configured to change between a first solid state and a second solid state.
C09K 5/06 - Substances qui subissent un changement d'état physique lors de leur utilisation le changement d'état se faisant par passage de l'état liquide à l'état solide, ou vice versa
C09K 5/14 - Substances solides, p. ex. pulvérulentes ou granuleuses
A granular hydrogel composition, preferably for the treatment of wounds, comprising a mixture of at least a plurality of first hydrogel microspheres, wherein the first hydrogel microspheres are formed of a first hydrogel scaffold material, and wherein the first hydrogel microspheres further comprise at least one growth factor compound, and at least a plurality of second hydrogel microspheres, wherein the second hydrogel microspheres are formed of a second hydrogel scaffold material, and wherein the second hydrogel microspheres further comprise at least a capturing compound for capturing a proinflammatory compound, wherein the capturing compound is bound to the second hydrogel scaffold material, and optionally a liquid aqueous phase.
A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
NATIONAL CHUNG HSING UNIVERSITY (Taïwan, Province de Chine)
Inventeur(s)
Neuhaus, Ekkehard
Bellin, Leo
Sonnewald, Uwe
Zierer, Wolfgang
Gruissem, Wilhelm
Abrégé
The present disclosure relates to genetically modified plants including a modified POTASSIUM TRANSPORTER 2 (AKT2) protein or an overexpressed AKT2 protein. The present disclosure further relates to methods of producing genetically modified plants including the modified AKT2 protein or the overexpressed AKT2 protein. In addition, the present disclosure relates to genetically modified plants with improved phloem transport, improved photosynthesis, higher rate of CO2 fixation and/or electron transport rate, increased yield under different growing conditions, and increased storage root or tuber growth.
An arrangement (1) for inserting an implant device (2) into biological tissue (4) comprises at least one implant device (2), and at least one insertion device (3). The insertion device (3) is configured to penetrate biological tissue (4). The implant device (2) and the insertion device (3) are configured to couple to one another via an implant-insertion coupling. The implant device (2), when being coupled to the insertion device (3) via the implant-insertion coupling, is insertable into the biological tissue (4) via the insertion device (3). The implant device (2) comprises at least one bundle (5) of fibers (6, 6a, …), and wherein the fibers (6, 6a, …) are coupled to one another via a fiber-fiber coupling, the implant-insertion coupling being different from the fiber-fiber coupling.
A61B 5/291 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/293 - Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
The present invention relates to a method for the determination of cleavage sites in genomic DNA caused by exposure to one or more site directed nucleases ("SDN") directed against one or more genomic target sequences (Fig. 7).
222 concentration changes, wherein the sensor comprises: two electrodes; and a sensing composite arranged between the two electrodes; wherein the sensing composite comprises: one or more carbon-based nanostructures having an outer surface; one or more metal-oxides functionalized to the outer surface of the one or more carbon-based nanostructures; and one or more photosensitizer capable of harvesting visible light, thereby inducing a photoconductance change in the underlying metal-oxide functionalized to the one or more carbon-based nanostructure, wherein said photosensitizers are functionalized to the outer surface of the one or more carbon-based nanostructures and/or the one or more metal-oxides.
G01N 27/12 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de l'absorption d'un fluideRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps solide dépendant de la réaction avec un fluide
Described is an exoskeleton device for assisted movement of a body member. The exoskeleton is for assisted movement of a member comprising a plurality of joints. The exoskeleton includes a first rigid section and a second rigid section positioned at respectively opposite ends of the member and an intermediate rigid section between the first and second rigid sections and positioned between the joints in the member. The exoskeleton also includes a repeating M structure comprising a plurality of length segments, each length segment extending between a respective pair of said rigid sections, and a drive spring extending at least from the first rigid section to the second rigid section, along an external region of the repeating M-structure, the drive spring between extendable and retractable to actuate the exoskeleton. A stiffness of each length segment is selected based on an amount of force to be applied to the member.
A filter assembly (1) for filtering a sample from a fluid (F) comprises a filter holder (4), a filter membrane (5), and a filter housing (6). The filter holder (4) is at least partially received in the filter housing (6), and the filter membrane (5) is attached to the filter holder (4) and is configured to filter a sample from a fluid (F) flowing from an inlet port (2) to an outlet port (3) through the filter membrane (5). The filter holder (4) is removably attached to the filter housing (6) such, that the filter holder (4) together with the filter membrane (5) is removable from the filter housing (6) and is insertable into a storage assembly (100) comprising a storage housing (20).
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
îîiîνν, the phase angle of the virtual internal voltage (formula (IV)) is controlled to match with the phase angle reference of the voltage reference (formula (I)) and the magnitude of the virtual internal voltage (formula (IV)) is adaptively changed depending on overcurrent conditions.
Catalyst assisted chemical etching of semiconductor substrate can achieve extreme aspect ratio (better than 1000:1), reproducibility and controlled etching quality for submicron feature size in the direction perpendicular to the substrate. The current patterning methods of the catalyst layer suffer of carbon contamination that affects the etching quality and limits the high-resolution pattern transfer in the semiconductor substrate for high aspect ratio etching. The present method allows to use semiconductor standard manufacturing processes to realize carbon-free pattern of catalyst layer by a physical separation with an interlayer material between the catalyst and the polymeric resist used in common lithographic methods. The present method allows to realize controlled predefined nanostructures with high resolution, high fidelity and high throughput yield during the catalyst assisted chemical etching of silicon for X-ray optics nanofabrication.
The present disclosure relates to a beamlet diffraction fringe generation method for attenuation, differential phase-contrast and dark-field imaging. By generating a fringe through structured diffraction beamlet arrays (Fig. 10) from structured diffraction beamlet array optics (10), an intensity variation is induced by superposition. As this effect does not rely on Talbot-carpet orders, it provides a tool for arbitrary fringe geometry and size generation at any distance.
The present invention relates to a highly efficient process for the photo-initiated depolymerization of vinyl polymers in the presence of at least one chlorine-containing reagent, preferably at elevated temperatures. The invention further relates to the recycling of vinyl polymers comprising the process according to the invention as well as the use of chlorine-containing reagents for the depolymerization of vinyl polymers.
C08J 11/20 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p. ex. dévulcanisation par traitement avec une substance organique par traitement avec des hydrocarbures ou des hydrocarbures halogénés
41.
A METHOD FOR DEFATTENING A STEATOTIC LIVER EX VIVO BY PERFUSION USING A PI4KB INHIBITOR
The present invention relates to a method for defattening a steatotic liver ex vivo, the method comprising perfusing a steatotic liver graft in a perfusion step using a perfusate comprising a PI4KB inhibitor as specified or a pharmaceutically acceptable salt or solvate thereof.
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A01N 1/126 - Agents physiologiquement actifs, p. ex. antioxydants ou nutriments
42.
MEDICAL DEVICE FOR USE AS URETERAL STENT, BILIARY STENT OR URINARY CATHETER IN A HUMAN OR ANIMAL BODY, MEDICAL SYSTEM COMPRISING SUCH A DEVICE AND METHOD OF ACOUSTICALLY ACTIVATING SUCH A DEVICE
The present invention relates to a medical device (100) for use as a ureteral stent, a biliary stent or a urinary catheter in a human or animal body. The medical device (100) comprises a hollow device body (101) having at least one body lumen (102), an inner body surface (105) and an outer body surface (106), wherein the inner body surface (105) delimits the at least one body lumen (102). The medical device (100) further comprises at least one array (110) of microstructures (111) located on the inner body surface (105) and/or the outer body surface (106) and configured to locally increase fluid-induced shear stress acting on the device body (101) in use of the medical device (100) in response to applying an acoustic field to the medical device (100). The invention further relates to a medical system comprising such as a medical device and an activation device configured to be positioned externally of a human or animal body, wherein the activation device comprises at least one sound transducer configured to generate an acoustic field for application from externally of the human or animal body to the medical device. The invention further relates to as to a method of acoustically activating such a medical device during use in a human or animal body, in particular for cleaning purposes and/or mass transport.
The invention relates to a device designed to measure and/or influence a property of a body fluid, in particular cerebrospinal fluid, provided in a fluidics module of the device. The device comprises the fluidic module, a reusable base part for receiving the fluidic module, a connecting tube or a tube coupling designed to connect the device to a body fluid source, in particular a patient, such that the body fluid can be guided through the connecting tube or the tube coupling into the fluidic module of the device, and a microfluidic chip arranged on or in the fluidic module and designed to influence the property of the body fluid.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
44.
TRAVELING WAVE PARAMETRIC AMPLIFIER AND MANUFACTURING METHOD, A METHOD FOR AMPLIFYING A TARGET SIGNAL, COMPUTER PROGRAM AND COMPUTER-READABLE DATA CARRIER
The invention relates to a traveling wave parametric amplifier (TWPA) for amplifying a target signal. The TWPA comprises a nonlinear transmission line (T1, T2) for receiving and propagating the target signal. The TWPA also comprises a plurality of coupling elements (DC1, DC2), wherein the plurality of coupling elements (DC1, DC2) are arranged at a distance from one another along the nonlinear transmission line (T1, T2). Each coupling element of the plurality of coupling elements (DC1, DC2) is configured to couple a pump signal portion from a pump feed line (D1) into the nonlinear transmission line (T1, T2), wherein the coupled-in pump signal portions form a total pump signal co-propagating in the nonlinear transmission line (T1, T2) in the same direction as the target signal for amplifying the target signal.
A process for screening a plasmid library encoding for peptides for one or more peptides that functionally activate a G protein-coupled receptor in a cell, by contacting the peptides with a cell expressing a G protein-coupled receptor, which functions as a sensor, and isolating the cells that functionally activate a G protein-coupled receptor to determine the sequence encoding the peptides.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12P 21/00 - Préparation de peptides ou de protéines
C40B 40/06 - Bibliothèques comprenant des nucléotides ou des polynucléotides ou leurs dérivés
A ring cavity laser (10) based on a semiconductor gain medium providing a lasing transition between quantised energy bands. The laser's ring cavity (12) possesses a plurality of modes, at least one of which having a frequency around which sufficient gain can be generated to cause lasing action. An electrical driver circuit applies an injection current to the semiconductor gain medium to cause population inversion and lasing action. A modulator (18) provides phase modulation within the cavity optical path at a modulation frequency near- resonant with an integer multiple or fraction of one of the mode frequencies. The phase modulation causes the laser to output a stable optical frequency comb which is established by random quantum walk in a photonic lattice created by said mode and its neighbouring resonator modes. A random quantum walk arises when these modes are coupled by the phase modulation.
H01S 5/065 - Accrochage de modesSuppression de modesSélection de modes
H01S 5/062 - Dispositions pour commander les paramètres de sortie du laser, p. ex. en agissant sur le milieu actif en faisant varier le potentiel des électrodes
H01S 5/10 - Structure ou forme du résonateur optique
H01S 5/34 - Structure ou forme de la région activeMatériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p. ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH]
47.
MICROFLUIDIC DEVICE AND METHOD FOR DETECTION OF BIOBURDEN
A microfluidic device comprises a flow channel (10) defining a flow direction (F), an array (20) of pillars (23) arranged in the flow channel (10), the array (20) comprising a supporting row (21) of pillars, the pillars of the supporting row (21) being separated by supporting row gaps (24) having a supporting row gap width (), and a membrane (30) comprising colloidal particles which are packed against the supporting row. At least some of the colloidal particles are larger than the supporting row gap width. Also disclosed is a method of manufacturing the device and a method of detecting bioburden using the device.
The invention relates to a method for assessing corrosion phenomena on at least one metal element (1), wherein an electrode (5) is in electrically conductive connection with an electrolyte volume (4) positioned outside a metal element (1) or a material (3) that is electrolytically conductive or can be made electrolytically conductive and that is at least partially covering the metal element (1), and wherein the electrolyte volume (4) is brought into electrically conductive contact with the metal element (1) or the material (3) via a stream (10) of electrolyte, and wherein an electrochemical measurement indicative of a state of corrosion on the metal element (1) is carried out. The invention further relates to a device (11) and a system (100) for assessing corrosion phenomena on at least one metal element (1).
A spectrometer assembly (1) for determining spectral information about incoming electromagnetic radiation (F) comprises a radiation conversion element (2) that comprises a non-centrosymmetric material to frequency-double at least a portion of the incoming electromagnetic radiation (F) as the incoming electromagnetic radiation (F) propagates through the radiation conversion element (2). The radiation conversion element (2) exhibits a spatially inhomogeneous structure such that the frequency-doubled electromagnetic radiation (SH) comprises components propagating in a plurality of different directions. The spectrometer assembly further comprises a detection unit (3) which is configured to record a spatial speckle image that is generated by spatial interference of the components of the frequency-doubled electromagnetic radiation (SH) with each other, and a computing unit (4) which is configured to retrieve spectral information about the electromagnetic radiation (F) based on said spatial speckle image.
A transceiver assembly (1) for receiving signals of a body tissue (2) and/or transmitting signals to a body tissue (2) comprises at least one holding device (3) and at least one transceiver device (4). The transceiver device (4) comprises at least one first transceiver- magnetic element (5) and the holding device (3) comprises at least one first holding-magnetic element (6), the first transceiver-magnetic element (5) and the first holding-magnetic element (6) being arranged after one another with respect to a connection direction (C) and being configured to exert a magnetic force to one another. The transceiver device (4) comprises at least one second transceiver-magnetic element (7) and the holding device (3) comprises at least one second holding-magnetic element (8) being arranged after one another with respect to a transverse direction (T) and are configured to exert a magnetic force to one another. The transceiver device (4) is connectable to the holding device (3) via an overall magnetic force exerted by the first and second transceiver-magnetic elements (5; 7) and by the first and second holding-magnetic elements (6; 8).
A61B 5/273 - Connexion des cordons, des câbles ou des fils conducteurs aux électrodes
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
H01R 13/62 - Moyens pour faciliter l'engagement ou la séparation des pièces de couplage ou pour les maintenir engagées
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
in vitroin vitro in vitro system for forming of a glycosylated peptide or polypeptide using said conjugate. The invention further concerns an enzymatic synthesis system for the formation of a glycan-conjugate of this invention. The invention further concerns a peptide or polypeptide with a glycosyl-moiety acceptor residue having an exogenous N-linked glycosylation sequence X1X2NYT, wherein X1is any one of alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), cysteine (C), tryptophan (W) and methionine (M), and wherein X2is either alanine (A) or valine (V), as well as an N-glycosylated conjugate of said peptide or polypeptide.
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C07H 13/00 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p. ex. acides phosphoniques
There is provided inter alia a process for the isolation of circulating tumour cell (CTC) clusters and/or circulating tumour cell-white blood cell (CTC-WBC) clusters comprising: (i) collecting an apheresis sample from a patient; (ii) debulking the apheresis sample of excess white blood cells; (iii) separating CTC clusters and/or CTC-WBC clusters from other components of the debulked apheresis sample using microfluidic separation; and (iv) isolating separated CTC clusters and/or CTC-WBC clusters; wherein the debulking step comprises a flow-based process where flow is driven by gravity and/or minimal applied artificial pressure; wherein the microfluidic separation is performed using a microfluidics device capable of separating CTC clusters and/or CTC-WBC clusters from other components of the debulked apheresis sample.
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
53.
PLATINUM CONTAINING CATALYST, METHOD OF PREPARATION, AND USE
JOHNSON MATTHEY PUBLIC LIMITED COMPANY (Royaume‑Uni)
ETH ZURICH (Suisse)
Inventeur(s)
Giulimondi, Vera
Johnston, Peter
Pérez-Ramírez, Javier
Smit, Joost Johannes
Abrégé
The invention provides a hydrochlorination catalyst, a method of manufacturing a hydrochlorination catalyst, and a process for catalytic hydrochlorination of a substrate containing an alkyne unit using the catalyst. The catalyst comprises a complex of Pt (II), wherein the complex is supported on a support.
The present invention relates to the field alcohol intoxication and its treatment and discloses novel hybrid materials and pharmaceutical compositions, their manufacturing, and their use in the context of excessive alcohol consumption. The hybrid materials disclosed comprise (a) amyloid proteins, such as fibrous amyloid proteins, and (b) a multitude of single-site iron coordinated to said amyloid proteins. These hybrid materials may be converted to hydrogels, pharmaceutical compositions comprising such hydrogels, and oral dosage forms comprising such hydrogels. Further disclosed are methods for manufacturing such hybrid material and hydrogels as well as methods of using such hybrid materials and hydrogels in the treatment of alcoholism.
An integrated device (1) comprises: a substrate (10), an electro-optic modulator antenna (11) arranged on the substrate (10) which is configured to receive a radio wave signal (30) and to convert an optical input signal (21) into an optical output signal (22) which depends on the radio wave signal (30), coupling elements (121, 122) arranged on the substrate (10) which are configured to optically couple the electro-optic modulator antenna (11) with fiber cores (41, 42) which are configured to receive the optical input signal (21) respectively to transmit the optical output signal (22).
H04B 10/90 - Systèmes de transmission non optiques, p. ex. systèmes de transmission utilisant un rayonnement corpusculaire non photonique
G02F 1/225 - Dispositifs ou dispositions pour la commande de l'intensité, de la couleur, de la phase, de la polarisation ou de la direction de la lumière arrivant d'une source lumineuse indépendante, p. ex. commutation, ouverture de porte ou modulationOptique non linéaire pour la commande de l'intensité, de la phase, de la polarisation ou de la couleur par interférence dans une structure de guide d'ondes optique
56.
STIFF AND DAMPING COMPOSITE STRUCTURES WITH THIN INTERLAYERS
A composite structure (1) for a damping structure (100) comprises at least one first layer (2), and at least one second layer (3) preferably comprising at least a first component (4) and optionally at least a second component (5). The first layer (2) and the second layer (3) are arranged above one another with respect to a thickness direction (D) of the composite structure (1). A thickness ratio h1/h2 between a thickness (h1) of the first layer (2) and a thickness (h2) of the second layer (3) along the thickness direction (D) is above 50, preferably above 100. The composite structure (1) has a loss flexural modulus E" above 1 GPa when measured at a temperature in the range of -50 °C to 100 °C and at a frequency in the range of 0.007 Hz to 10 Hz. The composite structure (1) has a product tanδ. (E'/p)1/2above 50 (Pa/kg/m3)1/2 at said temperature and at said frequency.
B32B 9/04 - Produits stratifiés composés essentiellement d'une substance particulière non couverte par les groupes comprenant une telle substance comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique
B32B 13/04 - Produits stratifiés composés essentiellement d'une substance à prise hydraulique, p. ex. du béton, du plâtre, du ciment, ou d'autres matériaux entrant dans la construction comprenant une telle substance comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique
B32B 13/12 - Produits stratifiés composés essentiellement d'une substance à prise hydraulique, p. ex. du béton, du plâtre, du ciment, ou d'autres matériaux entrant dans la construction comprenant une telle substance comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique de résine synthétique
B32B 17/10 - Produits stratifiés composés essentiellement d'une feuille de verre ou de fibres de verre, de scorie ou d'une substance similaire comprenant du verre comme seul composant ou comme composant principal d'une couche adjacente à une autre couche d'une substance spécifique de résine synthétique
B32B 25/20 - Produits stratifiés composés essentiellement de caoutchouc naturel ou synthétique comprenant du caoutchouc au silicone
B32B 27/28 - Produits stratifiés composés essentiellement de résine synthétique comprenant des copolymères de résines synthétiques non complètement couverts par les sous-groupes suivants
F16F 9/30 - Ressorts, amortisseurs de vibrations, amortisseurs de chocs ou amortisseurs de mouvement de structure similaire, utilisant un fluide ou moyen équivalent comme agent d'amortissement avec un matériau solide ou semi-solide, p. ex. des masses pâteuses, comme agent d'amortissement
The invention concerns a genetically modified cellulose producing bacterial strain comprising a reduction in expression of native gene encoding a ClpS polypeptide, or a deletion of the native gene encoding a native ClpS polypeptide, or comprising expressing or overexpressing a gene encoding a ClpA polypeptide containing a mutation or a deletion in the ClpS-binding region of said polypeptide, and/or expressing or overexpressing a gene encoding a ClpS polypeptide containing a mutation or deletion in the ClpA-binding region of said polypeptide, causing an alteration of binding affinity between the ClpS polypeptide and the ClpA polypeptide.
This invention concerns a method for providing genetically modified cells having a defined phenotype comprising providing a microorganism or a cell of a multicellular organism, performing random mutagenesis on said microorganism or said cell such as to obtain a population of genetically modified cells, optionally, incubating the population of genetically modified cells in the absence of light between 300 nm and 500 nm for a period of resting time. In a subsequent step, culturing the cells in growth medium for a period of recovery time, encapsulating of at least a portion of the genetically modified cells in a plurality of droplets, detecting the presence of a phenotypic marker which is indicative of a defined phenotype of the genetically modified cell in the droplets, and selecting the droplets comprising the detected phenotypic marker, or comprising a quantity of the detected phenotypic marker which exceeds a predefined threshold. The invention also concerns the use of the so fabricated droplets containing the genetically-modified cells with the desired phenotype for the production of macroscopic engineered living materials or other industrial applications.
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
59.
METHOD FOR DESIGNING GEOMETRICALLY FITTING AND STRUCTURALLY OPTIMIZED PATIENT-SPECIFIC IMPLANT MODELS AND METHOD FOR TRAINING AN ARTIFICIAL INTELLIGENCE MODEL FOR DESIGNING GEOMETRICALLY FITTING AND STRUCTURALLY OPTIMIZED PATIENT-SPECIFIC IMPLANT MODELS
The present invention relates to a computer-implemented method (100) for designing a geometrically fitting and structurally optimized patient-specific implant model (1) in view of its manufacturing.
The invention relates to a device (1) for investigating soil (2), comprising movement elements (10) for propulsion of the device (1) in the soil (2), wherein the device (1) is configured to determine a quantity of at least one physical parameter which is indicative of a force acting on at least one of the movement elements (10) when the respective movement element (10) moves in the soil (2). The invention also relates to a system (20) for investigating soil (2) as well as a method for investigating soil (2).
E02D 1/02 - Étude des sols de fondation sur place avant les travaux de construction
E21B 49/00 - Test pour déterminer la nature des parois des trous de forageEssais de couchesProcédés ou appareils pour prélever des échantillons du terrain ou de fluides en provenance des puits, spécialement adaptés au forage du sol ou aux puits
G01N 29/07 - Analyse de solides en mesurant la vitesse de propagation ou le temps de propagation des ondes acoustiques
61.
METHOD FOR SYNTHESIZING OLIGONUCLEOTIDES COMPRISING A CHIRALLY CONTROLLED PHOSPHOROTHIOATE LINKAGE
The present invention provides a method for synthesizing oligonucleotides comprising a least one chirally controlled internucleotide phosphorothioate linkage at the 3'- end. The invention further provides functionalized solid supports useful in such methods of oligonucleotide synthesis.
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
62.
ANTISENSE OLIGONUCLEOTIDES AND MEDICAL USE THEREOF
The present invention provides antisense oligonucleotides having a 2'-O-methoxy-ethyl sugar modification at each position and having at least one chiral internucleotide phosphorothioate linkage at the 3'-end with a Sp configuration. The invention further relates to the use of such antisensense oligonucleotides in medicine. The invention further provides compositions, including pharmaceutical compositions, comprising such antisense oligonucleotides. In addition, methods of manufacture are provided.
Method for the determination of at least one structural and/or physico-chemical property of at least one protein or peptide or of properties thereof, said at least one protein or peptide contained in a complex mixture of further proteins and/or other biomolecules in at least one cell, comprising the following steps: 1. delivery of a protease into said cell and limited proteolysis of the complex mixture, followed by cell extraction and/or cell lysis leading to a fragment sample; 2. denaturation of the fragment sample to a denaturated fragment sample; 3. optional complete fragmentation of the denaturated fragment sample in a digestion step to a completely fragmented sample; 4. analytical analysis of the fragmented sample or the completely fragmented sample for the determination of said at least one protein or peptide or of properties thereof.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12M 1/42 - Appareils pour le traitement de micro-organismes ou d'enzymes au moyen d'énergie électrique ou ondulatoire, p. ex. magnétisme, ondes sonores
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p. ex. par magnétisme, par des ondes sonores
A cross-linkable composition, preferably an additive manufacturing composition, comprising a mixture of at least a silicone-based vitrimer prepolymer and a precursor compound, and optionally silica and/or a photoinitiator, wherein the silicone-based vitrimer prepolymer has terminal thiol moieties and is the reaction product between an alkenyl-functionalized silicone, and a vitrimeric monomer, in a solvent, wherein the solvent is preferably an organic solvent, via a thiol-ene reaction, and wherein the precursor compound comprises at least three alkenyl moieties per molecule of precursor compound, and preferably is a silicone- based compound.
B29C 64/00 - Fabrication additive, c.-à-d. fabrication d’objets en trois dimensions [3D] par dépôt additif, agglomération additive ou stratification additive, p. ex. par impression en 3D, stéréolithographie ou frittage laser sélectif
B29C 73/16 - Dispositions ou agents d'autoréparation ou d'auto-obturation des perforations
C08G 77/392 - Polysiloxanes modifiés par post-traitement chimique contenant des atomes autres que le carbone, l'hydrogène, l'oxygène ou le silicium contenant du soufre
C08G 77/398 - Polysiloxanes modifiés par post-traitement chimique contenant des atomes autres que le carbone, l'hydrogène, l'oxygène ou le silicium contenant du bore ou des atomes métalliques
C08L 83/08 - Polysiloxanes contenant du silicium lié à des groupes organiques contenant des atomes, autres que le carbone, l'hydrogène et l'oxygène
65.
PH-INDUCIBLE STRUCTURE-SWITCHING LIPID NANOVECTORS, SEMI-SYNTHETIC EXTRACELLULAR VESICLES, METHODS OF MAKING SAME AND USES THEREOF
The present disclosure provides a pH-inducible structure-switching non-lamellar lipid nanovector (LNV) comprising: (a) at least one ionizable cationic lipid; (b) at least one phospholipid displaying a critical packing parameter (CPP) value > 1; and (c) at least one non-ionic surfactant displaying a CPP value < 1 at a molar concentration of between 20 % and 50 %, a method of making the LNV, a semi-synthetic extracellular vesicle (ssEV) resulting from the fusion of the LNV with extracellular vesicles at a pH higher than 6 and up to about 10, a kit and a use of the ssEV as a medicament or diagnostic agent.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention pertains to a composition or kit of parts comprising (1) coacervate-forming compounds, (2) a Cas complex comprising a guide RNA and a Cas protein, wherein the Cas protein has trans or collateral cleavage activity for a nucleic acid sequence of a reporter, (3) a reporter comprising a detection moiety covalently linked to the nucleic acid sequence, wherein the nucleic acid sequence is suitable for being cleaved by the Cas complex, and the detection moiety is suitable for optical or electrochemical detection; and (4) optionally a target suitable for activating the Cas complex, wherein at least one, two or three of the coacervate-forming compounds, the Cas complex, the reporter, the cleaved detection moiety and/or the target are configured such that at least one, two or three of the Cas complex, the reporter, the cleaved detection moiety and/or the target are taken up by coacervates formed by the coacervate-forming compounds. The present invention further pertains to associated uses and methods for detection.
The invention relates to a rocking bed (1), comprising a slider-crank mechanism (2 comprising a rotary drive (3) and at least one four-bar linkage (4) comprising a frame (5) with two cranks (6) pivotably mounted thereon via a first pivot (P1) and a second pivot (P2), and a movable linkage (7) pivotably connected to the cranks via a third pivot (P3) and a fourth pivot (P4), wherein a connecting rod (21) of the slider-crank mechanism (2) is pivotably connected to a support structure (8) of the rocking bed (1) via a sixth pivot (P6), wherein there is a pivotable connection between the movable linkage (7) and the support structure (8) of the rocking bed (1) via a fifth pivot (P5), via which a movement of the support structure (8) can be guided along a horizontal direction and wherein the rotary drive (3) has a control unit configured to realize a revolution operation of a crank (22) of the slider-crank mechanism (2). The invention also relates to a method as well as a computer program for operating such a rocking bed (1).
A47C 21/00 - Accessoires de lits, p. ex. articles pour tenir les draps, les couvertures ou dessus de litMoyens de ventilation, de refroidissement ou de chauffage reliés aux lits ou aux matelas
68.
SINGLE-CELL CRISPR-SCREENING OF MULTIPLE GENE PERTURBATIONS IN VIVO
The present invention relates to a method allowing for a single-cell-based analysis of multiple CRISPR-mediated gene perturbations in a single organism. The method comprises the administration of a plurality of viral expression vectors each encoding a gRNA into an organism expressing a Cas enzyme, and allows for analysis of the resulting phenotype on a single-cell level.
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
The invention relates to a device (100) for applying force to an object for positioning and/or fixation of the object, comprising a first member (10) and a second member (20) hingedly connected to the first member (10), wherein the first member (10) has a curved guide surface (11) for forming a hinge connecting the members (10, 20), which curved guide surface (11) is formed for guiding the second member (20) on this curved guide surface (11), wherein the first member (10) comprises a longitudinal axis (L1) that extends in the same plane as a tangent (T1) on the guide surface (11) of the first member (10), the tangent (T1) being at an acute angle to the longitudinal axis (L1) and the curved guide surface (11) being curved at least about the longitudinal axis (L1), and wherein the second member (20) comprises a surface (21) with which this second member (20) can roll on the guide surface (11) of the first member (10). The invention also relates to a gripper, a robot, as well as a method for handling at least one object.
The invention relates to a device (100) for applying force to an object positioning and/or fixation of the object, comprising a first member (10) and for contacting the object a second member (20), hingedly connected to the first member (10) via a hinge unit (600) having two degrees of rotational freedom, and a tensioning system (625) comprising two pairs of traction elements (640,660) fixed to the second member (20), wherein the first pair of traction elements (640) is mounted to a first spool set (630) and the second pair of traction elements (660) is mounted to a second spool set (650), and wherein the first traction element (641) of the first pair (640) is mounted to a first spool (631) of the first spool set (630), and the second traction element (642) of the first pair (640) is mounted to a second spool (632) of the first spool set (630), and the first traction element (661) of the second pair (660) is mounted to a first spool (651) of the second spool set (650) and the second traction element (662) of the second pair (660) is mounted to a second spool (652) of the second spool set (650), wherein the two degrees of rotational freedom of the hinge unit (600) exist in two theoretical movement planes being perpendicular to each other, and wherein fixing points (690) at the traction elements (641, 642, 661, 662) on the second member (20) are positioned in connection planes outside the movement planes. The invention further relates to a gripper, a robot as well as a method for handling at least one object.
The present invention relates to an improved porous solid catalyst (C) adapted for the conversion of methanol and derivatives thereof into low-molecular weight hydrocarbons, based on a zeolite, such as ZSM-5, and on inorganic oxide, such as ceria, in a preferable weight ratio of zeolite:inorganic oxide between 1:1 and 1:5. It further relates to a conversion process and to a system using such a catalyst.
B01J 38/12 - Traitement avec un gaz contenant de l'oxygène libre
C01B 39/02 - Zéolites aluminosilicates cristallinesLeurs composés isomorphesLeur préparation directeLeur préparation à partir d'un mélange réactionnel contenant une zéolite cristalline d'un autre type, ou à partir de réactants préformésLeur post-traitement
C10G 3/00 - Production de mélanges liquides d'hydrocarbures à partir de matières organiques contenant de l'oxygène, p. ex. huiles, acides gras
C07C 1/20 - Préparation d'hydrocarbures à partir d'un ou plusieurs composés, aucun d'eux n'étant un hydrocarbure à partir de composés organiques ne renfermant que des atomes d'oxygène en tant qu'hétéro-atomes
B01J 23/92 - Régénération ou réactivation de catalyseurs contenant des métaux, oxydes ou hydroxydes prévus dans les groupes
B01J 29/70 - Zéolites aluminosilicates cristallinesLeurs composés isomorphes de types caractérisés par leur structure spécifique non prévus dans les groupes
72.
COMPOSITION COMPRISING MODIFIED DNA IDENTIFIER SEQUENCES FOR DNA MODIFICATION SCREENING
The present invention is directed to composition comprising modified DNA identifier sequences (MoDIS) comprising (i) a validation code nucleotide sequence (VC), (ii) a randomized index code nucleotide sequence (RIC) and (iii) an annealing site nucleotide sequence (AS) for specifically binding a primer for PCR amplification, wherein (a) AS is attached to an affinity tag or marker and/or affinity tag compound for the identification, enrichment and/or purification of MoDIS-bound nucleotide sequences; and (b) the nucleotide at the 5'-end of the MoDIS comprises a 5'- azido-modified moiety or a 5'-alkynyl-modified moiety.
The present invention relates to a separation process for rare earth element compounds by converting a mixture of rare earth element compounds into novel thiometallate complexes which exhibit substantially different structures and thus solubility depending on the rare earth metals employed in said process and their state of oxidation. The invention further encompasses the thiometallate complexes as such.
C01F 17/10 - Préparation ou traitement, p. ex. séparation ou purification
C01F 17/17 - Préparation ou traitement, p. ex. séparation ou purification faisant intervenir une extraction liquide-liquide
C22B 3/16 - Extraction de composés métalliques par voie humide à partir de minerais ou de concentrés par lixiviation dans des solutions organiques
C22B 3/26 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques
C22B 3/38 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par extraction liquide-liquide utilisant des composés organiques contenant du phosphore
C22B 59/00 - Obtention des métaux des terres rares
The invention is notably directed to a composition including a plurality of double-stranded oligodeoxynucleotides (dsODNs). The dsODNs of said plurality have a same length of between 47 and 300 bp (e.g., between 80 and 150 bp, or between 85 and 130 bp). The dsODNs are structured according to a same template structure, which consists of an orderly set of sequence portions having respective lengths that are constant across all the dsODNs of said plurality. The orderly set of sequence portions includes a first random segment, a first sequencing adapter, a second random segment, a second sequencing adapter, and a third random segment. Such segments are consecutively arranged to form a sequence. Each of the random segments of the dsODNs of said plurality consists of essentially random permutations of nucleotides, whereas the first and second sequencing adapters of the dsODNs of said plurality consist, independently of each other, of essentially a same sequence of nucleotides. The above template structure gives rise to partly random DNA, which can be operated for verification and/or authentication purposes. The above sequence structure allows the composition to be used as a mathematical one-way function and as a physical unclonable function (PUF). I.e., it can be used as a physical fingerprint, which can be challenged to verify or authenticate a product, an object, or any entity, with which the composition is associated. The same composition can be subjected to multiple challenges, hence providing higher certainty as to an associated entity. The underlying technology is scalable. Samples of the composition can be distributed to multiple users, unlike usual PUF objects. Accordingly, the proposed composition can adequately be used for securing objects or entities. The invention is further directed to methods of producing such a composition, the use of such a composition, a set comprising such a composition associated with an entity, and methods of verifying entities associated with such compositions.
Ex vivo tissue culturing and sampling system (2) comprising a microfluidic cartridge (4) and a microfluidic sampling apparatus (3) that receives the microfluidic cartridge and a tissue support substrate (5) on which a tissue sample (1) to be cultured and analysed is mounted, the tissue support substrate separable from the microfluidic cartridge and comprising a porous hydrophilic membrane (19), the microfluidic cartridge comprising - a body (10), - a reaction chamber (20) formed within the body and configured to be sealingly closed by a seal (24) around the tissue sample (1) on the tissue support substrate (5), and - a transparent observation window (16) bounding one side of the reaction chamber configured to allow microscope imaging of the tissue sample, the microfluidic sampling apparatus comprising - a cartridge holder (6) in which the microfluidic cartridge and biological sample support substrate is removably mounted, - a reagent fluid flow system (7) configured to pump liquid through the microfluidic cartridge reaction chamber, and - a gas to liquid diffusion device (8) connected to the reagent fluid flow system upstream of the microfluidic cartridge reaction chamber.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
76.
A MICROELECTRODE DEVICE FOR SENSING A BIOLOGICAL ACTIVITY WITHIN A SAMPLE AND A METHOD OF USING SUCH A MICROELECTRODE DEVICE
A microelectrode device (1) for sensing a biological activity within a sample (S), the microelectrode device (1) comprises an electrode assembly (11) with electrodes (11.1, 11.2; 11.r, 11.c) for contacting the sample (S), and an electronic equipment (12) which is connected to the electrodes (11.1, 11.2; 11.r, 11.c) of the electrode assembly (11). The electronic equipment (12) is configured to evaluate one or more capacitances (C; C0, C1,...) between the electrodes (11.1, 11.2; 11.r, 11.c) for sensing the biological activity within the sample (S). The microelectrode device (1) enables that the one or more capacitances (C; C0, C1,...) include one or more electrical double layer capacitances (C_EDL) of one or more electrical double layers which are formed when the electrodes (11.1, 11.2; 11.r, 11.c) are brought into contact with the sample (S).
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/94 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des narcotiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/483 - Analyse physique de matériau biologique
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
EMPA EIDGENOESSISCHE MATERIALPRUEFUNGS- UND FORSCHUNGSANSTALT (Suisse)
ETH ZÜRICH (Suisse)
Inventeur(s)
Jessernig, Alexander
Herrmann, Inge Katrin
Anthis, Alexandre Herrmann Christos
Abrégé
The present invention relates to the use of a biosensor to detect a postoperative leak with a patient's drain fluid, relating to an operation selected from the group consisting of pancreatic anastomosis, pancreatic resection, small colon anastomosis (also called small intestine anastomosis), large intestine anastomosis, colorectal surgery, colon bypass surgery, gastric bypass surgery, gastric resection surgery, cholecystectomy, bileduct surgery and oesophageal surgery, and wherein said biosensor comprises at least one gel which is placed on a support layer, and wherein the at least one gel is sensitive to a digestive enzyme and comprises a colorant selected from the group consisting of an organic dye, an inorganic dye, an organic pigment and an inorganic pigment, and wherein said at least one gel degrades upon contact with a drain fluid comprising one or more digestive enzymes, allowing a visual detection of discoloration of the gel or disappearance at the place where the gel was before, and/or a coloration of the drain fluid.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
A photodetector (8) comprises: a multilayer stack comprising a resonator layer (1) which is in contact with a 2D material layer (3) which is in contact with an insulator spacer layer (4), wherein the multilayer stack is configured to absorb an optical signal and to convert the absorbed optical signal into charge carriers and to enable electrically measuring the charge carriers, wherein the 2D material layer (3) includes one or more layers of a 2D material, wherein the resonator layer (1) comprises first and second contact lines (1a1, 1a2) which have an alternating configuration, wherein the first and second contact lines (1a1, 1a2) include different materials, wherein at least one of the first and second contact lines (1a, 1a2) has arranged resonators (1b, 1b1, 1b2, 1bb, 1bb1, 1bb2, 1bbb).
H01L 31/028 - Matériaux inorganiques comprenant, à part les matériaux de dopage ou autres impuretés, uniquement des éléments du groupe IV de la classification périodique
H01L 31/036 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails caractérisés par leurs corps semi-conducteurs caractérisés par leur structure cristalline ou par l'orientation particulière des plans cristallins
H01L 31/102 - Dispositifs sensibles au rayonnement infrarouge, visible ou ultraviolet caractérisés par une seule barrière de potentiel ou de surface
G02B 6/12 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques du genre à circuit intégré
H01L 31/0232 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails - Détails Éléments ou dispositions optiques associés au dispositif
79.
CULTIVATION MEDIUM AND METHOD OF CULTIVATING MICROALGAE
The present invention relates to a cultivation medium, a method of preparing a cultivation medium and a method of cultivating heterotrophic microalgae. The cultivation medium comprises a mixed hydrolysate medium containing 15% to 25% v/v soy whey hydrolysate and 75% to 85% v/v brewer's spent grain hydrolysate, based on the total volume of the mixed hydrolysate medium, wherein the cultivation medium is rich in endogenous glucose, having an endogenous glucose density of 46.0 to 51.0 g/L, for supporting growth of heterotrophic microalgae. The method of the present invention yields relatively high amount of microalgal biomass and provides increased biomass production.
A23J 1/00 - Préparation des compositions à base de protéines pour l'alimentationOuverture des œufs par grandes quantités et séparation du jaune du blanc
A method for collecting environmental DNA from a space (101) within a plant canopy (100) comprises: providing a UAV (1) comprising a propulsion system (2) and a probe (3) hanging from the propulsion system (2); providing the probe (3) with a sampling material (5); flying the UAV 5 (1) with the propulsion system (2) at a height (H) over the plant canopy (100); dipping the probe (3) into the plant canopy (100); brushing the sampling material (5) against a plant surface (102) in the space (101) within the plant canopy (100); and extracting the probe (3) from the plant canopy (100).
B64D 1/22 - Enlèvement d'objets à la surface du sol
B64U 101/35 - Véhicules aériens sans pilote spécialement adaptés à des utilisations ou à des applications spécifiques à la science, p. ex. à la météorologie
B64U 101/40 - Véhicules aériens sans pilote spécialement adaptés à des utilisations ou à des applications spécifiques à l’agriculture ou à la sylviculture
H03L 7/093 - Détails de la boucle verrouillée en phase concernant principalement l'agencement de détection de phase ou de fréquence, y compris le filtrage ou l'amplification de son signal de sortie utilisant des caractéristiques de filtrage ou d'amplification particulières dans la boucle
H03L 7/197 - Synthèse de fréquence indirecte, c.-à-d. production d'une fréquence désirée parmi un certain nombre de fréquences prédéterminées en utilisant une boucle verrouillée en fréquence ou en phase en utilisant un diviseur de fréquence ou un compteur dans la boucle une différence de temps étant utilisée pour verrouiller la boucle, le compteur comptant entre des nombres variables dans le temps ou le diviseur de fréquence divisant par un facteur variable dans le temps, p. ex. pour obtenir une division de fréquence fractionnaire
The invention relates to a CjCas9 variant characterized by at least one of the mutations E789K and S951G. The invention further relates to base editing enzymes comprising the Cas variant according to the invention and an adenosine deaminase activity, and to polynucleotides encoding same.
One or more transmitters (TX1, …, TXU; TX) and a receiver (RX) of a MIMO communication system (1) enable mitigation of a jammer (TXJ). The one or more transmitters (TX1, …, TXU; TX) are configured to generate an embedded signal (X) by embedding a transmit signal (S) with a linear time-domain transformation onto a secret subspace (subC) based on a secret unitary matrix (C; C1, …, CU) which is accessible to the transmitters (TX1, …, TXU; TX) and the receiver (RX), and to transmit the embedded signal (X) via MIMO communication having a legitimate channel matrix (H) to the receiver (RX). The receiver (RX) is configured to receive a receive signal (Y) which includes the embedded signal (X) and to process the receive signal (Y) for determining an estimate (~S) of the transmit signal (S) by extracting the transmit signal (S) from the secret subspace (subC) using the secret unitary matrix (C; C1, …, CU).
The present invention relates generally to a method for producing organoids, and more specifically to a method for producing human retinal organoids. The present invention further relates to a method for the automated generation of mammalian retinal organoids comprising continuous in vitro culturing of pluripotent stem cells and descendants thereof, which allows for the reproducible and efficient generation of human retinal organoids in large numbers. The invention further relates to producing organoids from stem cells that are derived from humans or other mammals that are healthy or have a disease. The present invention also relates to compositions and methods for the assessment of drug toxicity, efficacy, and other therapeutic agent properties or for the treatment of retinal diseases or for retinal organoid protocol development. The organoids of the invention are useful for the treatment of retinal diseases, for medical or biomedical assays, and as diagnostic tools for screening drugs or other compounds or developing therapeutic treatments for retinal diseases.
CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA (Suisse)
Inventeur(s)
Deshmukh, Dhananjay
Tibbitt, Mark
Dual, Jürg
Weder, Gilles
Vuille-Dit-Bille, Emilie
Abrégé
It is thus a first object of the present invention to provide a process for the production of a microtome block comprising biological samples, wherein in said microtome block, the biological samples are concentrated in one plane and which biological samples are concentrated in said plane via acoustofluidic methods.
Systems and methods are provided to provide a prediction for a physiological parameter of a patient to a clinical decision support tool. For that purpose, a real-time or near real-time data stream is accessed of measured values of a physiological parameter of a patient. A trained machine learning model is used to generate, using a time-series of measured values from the real-time or near real-time stream as input, a time-series of predicted values as output. It is determined whether predicted values fall within a physiological range associated with the physiological parameter, thereby obtaining a time- series of classifications, wherein a respective classification is indicative of whether a predicted value falls inside or outside of the physiological range. The time-series of classifications provided to the clinical decision support tool, for example to visualize the time- series of classifications in a graphical representation of a patient's medical condition.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
87.
SHEAR THINNING TWO-PHASE COMPOSITION AND PRODUCTS MADE THEREOF
EMPA EIDGENÖSSISCHE MATERIALPRÜFUNGS- UND FORSCHUNGSANSTALT (Suisse)
ETH ZÜRICH (Suisse)
Inventeur(s)
Danner, Patrick Marcel
Opris, Dorina Maria
Pleij, Tazio
Bayles, Alexandra Victoria
Vermant, Jan
Abrégé
The present invention pertains to a shear thinning two-phase composition based on polysiloxanes and a filler. The invention is further directed to associated methods of manufacturing the composition, to the use of the composition as an ink and to products made from the composition.
C08J 3/05 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension dans un milieux aqueux à partir de polymères solides
88.
APPARATUS AND METHOD FOR LEAKAGE REDUCTION IN A QUANTUM COMPUTING DEVICE
An apparatus comprises a qubit (100), a resonator structure (200) coupled to the qubit, and a frequency-modulation device (300) coupled to the qubit. For converting leakage errors into errors in the computational subspace, the frequency modulation device applies a frequency modulation pulse to the qubit, which causes periodic modulation of the qubit frequency. The frequency modulation pulse is applied in such a manner that population transfer between a leakage state and the first excited qubit state is facilitated while population transfer between the computational states of the qubit is suppressed.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G06N 10/70 - Correction, détection ou prévention d’erreur quantique, p. ex. codes de surface ou distillation d’état magique
89.
METHODS OF OBTAINING KERATIN PROTEIN ISOLATE, KERATIN AMYLOID FIBRILS AND FABRICATING MEMBRANES USING THE SAME
The present invention relates to a method of obtaining keratin protein isolate from a keratin source, the method comprising: (a) preparing a first mixture comprising keratin source, chaotropic solvent, and a first reducing agent; (b) precipitating keratin protein from the first mixture; (c) preparing a second mixture comprising the keratin protein and a second reducing agent; and (d) precipitating keratin protein isolate from the second mixture. The present invention also relates to a method of obtaining keratin amyloid fibrils, the method comprising: (i) obtaining keratin protein isolate; (ii) preparing a third mixture comprising keratin protein isolate, acid solution, and a third reducing agent; and (iii) subjecting the third mixture to heat treatment to obtain keratin amyloid fibrils. The present invention also relates to a method of fabricating a membrane for an electrochemical cell or a proton conductive cell.
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
The present invention is directed to a method for introducing charged compounds into three-dimensional biological tissues comprising the step of introducing at least one charged compound of interest into the biological tissue, wherein a composition for dissolving and removing lipids and/or a composition for introducing at least one charged compound of interest into the bio- logical tissue is injected into the biological tissue and a pulsed electrical field (PEF) is applied to the biological tissue. The invention further relates to a device for use in this method, and a use of this method or this device for histological staining.
According to the present invention there is provided a method for providing a conductive polymer material (9) on a fabric (1), the method comprising the steps of, (a) providing a fabric (1); (b) impregnate the fabric (1) with oxidant (2); (c) exposing the fabric (1) to a monomer vapor (7) so that the monomer vapor (7) reacts with the oxidant (2) impregnated in the fabric (1) to generate a conductive polymer material (9) on the fabric (1). There is further provided a fabric comprising a conductive polymer material formed using the method of the present invention.
D06M 11/28 - Halogénures d'éléments des groupes 8, 9, 10 ou 18 du tableau périodique
D06M 11/48 - Oxydes ou hydroxydes de chrome, de molybdène ou de tungstèneChromatesDichromatesMolybdatesTungstates
D06M 11/50 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec de l'oxygène, de l'ozone, des ozonides, des oxydes, des hydroxydes ou des percomposésSels dérivés d'anions avec une liaison élément amphotère-oxygène avec du peroxyde d'hydrogène ou des peroxydes de métauxTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec de l'oxygène, de l'ozone, des ozonides, des oxydes, des hydroxydes ou des percomposésSels dérivés d'anions avec une liaison élément amphotère-oxygène avec des acides persulfuriques, permanganiques, pernitriques, percarboniques ou leurs sels
D06M 11/83 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec des métauxTraitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec des composés libérant des métaux, p. ex. des métaux-carbonylesRéduction de composés métalliques sur des textiles
D06M 15/356 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone d'autres composés non saturés contenant des atomes d'azote, de soufre, de silicium ou de phosphore
D06M 23/14 - Procédés pour la fixation ou le traitement de matériaux textiles sous forme tridimensionnelle
A method for producing a nano- or micro-sheet element is provided, the nano- or micro-sheet element particularly being made of graphene and/or other sheet-materials. The method is based on a laminate (14) comprising a growth substrate (1), a nano- or micro-sheet layer (2) and a support layer (3). The nano- or micro-sheet layer (2) is adapted to form the nano- or micro-sheet element. The method comprises at least the step of electrochemical delamination of the laminate (14) by means of electrolysis in such a way, that the growth substrate (1) is separated from the nano- or micro-sheet layer (2) and the support layer (3). The step of electrochemical delamination of the laminate (14) is carried out with the support layer (3) having a pattern (31) with a plurality of local depressions (311) and/or elevations (312).
The present invention is generally in the fields of synthetic biology, gene therapy, and cell therapy. The invention relates, inter alia, to a synthetic transcription factor comprising a DNA binding domain derived from a mitochondrial DNA binding protein (e.g. MTERF1) and a transcriptional modulation domain derived from one or more other proteins; a nucleic acid or combination of nucleic acids encoding the inventive synthetic transcription factor; a DNA construct comprising a MTERF1 binding site and a minimal promoter; a system comprising the inventive synthetic transcription factor and the inventive DNA construct; and uses thereof, e.g. medical uses.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C40B 40/06 - Bibliothèques comprenant des nucléotides ou des polynucléotides ou leurs dérivés
A61K 38/00 - Préparations médicinales contenant des peptides
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
95.
SUBSTRATE FOR PREVENTING A FLUID FROM MISTING AN ARTICLE
A substrate (1) for preventing a fluid (2) from misting, in particular from fogging, an article (3) comprises at least one surface (4) comprising a surface structure (5). The surface structure (5) is formed by a plurality of protrusions (6) and a plurality of indentations (7) extending along an extension direction (E). The surface structure (5) is configured to generate capillary forces on a fluid (2) such, that the fluid (2) forms a fluid layer (8) among the surface structure (5).
A method for producing a nano- or micro-sheet element is provided, the nano- or microsheet element particularly being made of graphene and/or other sheet-materials. The method is based on a laminate (14) comprising at least a growth substrate (1) and a nano-or micro-sheet layer (2). The nano- or micro-sheet layer (2) is adapted to form the nano- or micro-sheet element. The method comprises at least the step of electrochemical delamination of the laminate (14) by means of electrolysis in such a way, that the growth substrate (1) is separated from the nano- or micro-sheet layer (2). In the electrochemical delamination of the laminate (14), a gas diffusion electrode (21) attached to the nano- or micro-sheet layer (2) is used as an anode and an electrolyte membrane, in particular a polymer electrolyte membrane (20), is arranged between the gas diffusion electrode (21) and the nano- or micro-sheet layer (2).
The invention relates to a method, system and computer program for determining a tracer flow in a measurement space, the method comprising the steps of: • a) Injecting tracers at a first injection region into the measurement space with a tracer seeding device configured to inject tracers at an adjustable injection region in the measurement space, • b) Recording the measurement space with two or more event-cameras, wherein each event-camera comprises a plurality of sensors configured to generate output data each time a sensor of the event camera senses a change in light intensity, wherein the output data comprises an information on a position of the sensor that sensed the change in light intensity, and a time of the change in light intensity, • c) From the data of the event-cameras, determining with a processor for at least some of the injected tracers a trajectory in the measurement space, wherein each trajectory comprises at least an information on a time-resolved three-dimensional position of the tracer, wherein the determination of the trajectories is facilitated in real time, • d) While executing steps b) and c), adjusting the injection region to at least a second injection region different from the first injection region.
G01P 5/20 - Mesure de la vitesse des fluides, p. ex. d'un courant atmosphériqueMesure de la vitesse de corps, p. ex. navires, aéronefs, par rapport à des fluides en mesurant le temps mis par le fluide à parcourir une distance déterminée en utilisant des particules entraînées par un courant de fluide
G01M 9/06 - Dispositions pour la mesure spécialement adaptées aux tests aérodynamiques
98.
COMPLEMENT COMPONENT 7 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET
The present invention relates to a method for predicting the likelihood of developing, or of diagnosing, a systemic post-infection syndrome via measuring the amount of C7 in a patient sample, particularly the amount of liquid-phase (soluble) or complexed C7. The invention particularly relates to the diagnosis of long COVID. The invention further relates to a treatment or prevention of a systemic post-infection syndrome via administering to a patient an agent able to mimic or modulate the biological activity of C7.
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
99.
METHOD FOR IDENTIFYING A MODIFIED AMINO ACID DEGRON (MAAD)
The present invention relates to a method for identifying a modified amino acid degron (MAAD) and factors mediating the selective degradation of a protein tagged with the MAAD.
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
C40B 30/08 - Procédés de criblage des bibliothèques en mesurant l'activité catalytique
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
100.
ANALYTICAL COMPOSITION FOR MONITORING DISINFECTION
The present invention relates to analytical compositions and kits, their use for monitoring disinfection procedures, and a method for monitoring a disinfection procedure. The analytical composition comprises lipid nanoparticles encapsulating a nucleic acid.